Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JS7 plasmid DNA and MVA62B vaccine · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| JS7 plasmid DNA and MVA62B vaccine | BIOLOGICAL | JS7 plasmid DNA (3 mg at weeks 1 and 9) and MVA62B vaccine (10(8) TCID(50) at weeks 17 and 25) |
Top 20 of 28 competitors
JS7 plasmid DNA and MVA62B vaccine is an investigational vaccine being studied for HIV-1 infection. It is designed for HIV-1 infected adults who are on antiretroviral therapy (ART). The vaccine is currently in Phase 1 clinical development and is not yet approved for use.
JS7 plasmid DNA and MVA62B vaccine is being developed by GeoVax Labs, Inc., a biopharmaceutical company. GeoVax Labs is publicly traded under the ticker symbol GOVX on the stock market.
JS7 plasmid DNA and MVA62B vaccine is in Phase 1 clinical development. It is an investigational vaccine, meaning it has not been approved by regulatory authorities and is still being studied for safety and immunogenicity in clinical trials.
JS7 plasmid DNA and MVA62B vaccine has been studied in one clinical trial, identified as NCT01378156. This Phase 1 trial, titled 'A Safety and Immunogenicity Study of a Plasmid DNA Prime and MVA Boost Vaccine in HIV-1 Infected Adults on ART,' has been completed and enrolled 9 participants.
JS7 plasmid DNA and MVA62B vaccine is a combination vaccine that includes both a plasmid DNA component (JS7) and a modified vaccinia Ankara (MVA) component (MVA62B). The vaccine uses a prime-boost strategy, with the plasmid DNA priming the immune system and the MVA boosting the response.